Oprozomib in patients with newly diagnosed multiple myeloma

被引：17

作者：

Hari, Parameswaran ^{[1
]}

Matous, Jeffrey V. ^{[2
]}

Voorhees, Peter M. ^{[3
]}

Shain, Kenneth H. ^{[4
]}

Obreja, Mihaela ^{[5
]}

Frye, John ^{[5
]}

Fujii, Hisaki ^{[5
]}

Jakubowiak, Andrzej J. ^{[6
]}

Rossi, Davide ^{[7
]}

Sonneveld, Pieter ^{[8
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[2] Colorado Blood Canc Inst, Denver, CO USA

[3] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[7] Univ Piemonte Orientale, Novara, Italy

[8] Erasmus MC Canc Inst, Rotterdam, Netherlands

来源：

BLOOD CANCER JOURNAL | 2019年 / 9卷 / 9期

关键词：

DEXAMETHASONE; CARFILZOMIB; CYCLOPHOSPHAMIDE; LENALIDOMIDE; MULTICENTER;

D O I：

10.1038/s41408-019-0232-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 10 条

[1] A Multicenter, Open-Label, Phase 1b Study of Carfilzomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients (CHAMPION-2) [J].

Boccia, Ralph V. ;

Bessudo, Alberto ;

Agajanian, Richy ;

Conkling, Paul ;

Harb, Wael ;

Yang, Hui ;

Pinchasik, Dawn ;

Kimball, Amy S. ;

Berenson, James R. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07) :433-437

[2] Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study [J].

Bringhen, Sara ;

Petrucci, Maria Teresa ;

Larocca, Alessandra ;

Conticello, Concetta ;

Rossi, Davide ;

Magarotto, Valeria ;

Musto, Pellegrino ;

Boccadifuoco, Luana ;

Offidani, Massimo ;

Omede, Paola ;

Gentilini, Fabiana ;

Ciccone, Giovannino ;

Benevolo, Giulia ;

Genuardi, Mariella ;

Montefusco, Vittorio ;

Oliva, Stefania ;

Caravita, Tommaso ;

Tacchetti, Paola ;

Boccadoro, Mario ;

Sonneveld, Pieter ;

Palumbo, Antonio .

BLOOD, 2014, 124 (01) :63-69

[3] Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies [J].

Cavaletti, Guido ;

Jakubowiak, Andrzej J. .

LEUKEMIA & LYMPHOMA, 2010, 51 (07) :1178-1187

[4] Myeloma: management of the newly diagnosed high-risk patient [J].

Dispenzieri, Angela .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :485-494

[5] Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma [J].

Ghobrial, Irene M. ;

Badros, Ashraf Z. ;

Vredenburgh, James J. ;

Matous, Jeffrey ;

Caola, Aaron M. ;

Savell, Alexandra ;

Henrick, Patrick ;

Paba-Prada, Claudia E. ;

Schlossman, Robert L. ;

Laubach, Jacob P. ;

Rosenblatt, Jacalyn ;

Yee, Andrew ;

Wisch, Jeffrey S. ;

Farber, Charles M. ;

Maegawa, Rodrigo O. ;

Usmani, Saad Z. ;

Cappuccio, Joseph ;

Rivotto, Bradley ;

Noonan, Kimberly ;

Reyes, Kaitlen ;

Munshi, Nikhil C. ;

Anderson, Kenneth C. ;

Richardson, Paul .

BLOOD, 2016, 128 (22)

[6]

Hari P.N., 2014, Blood, V124, P3453, DOI DOI 10.1182/BLOOD.V124.21.3453.3453

[7] A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma [J].

Jakubowiak, Andrzej J. ;

Dytfeld, Dominik ;

Griffith, Kent A. ;

Lebovic, Daniel ;

Vesole, David H. ;

Jagannath, Sundar ;

Al-Zoubi, Ammar ;

Anderson, Tara ;

Nordgren, Brian ;

Detweiler-Short, Kristen ;

Stockerl-Goldstein, Keith ;

Ahmed, Asra ;

Jobkar, Terri ;

Durecki, Diane E. ;

McDonnell, Kathryn ;

Mietzel, Melissa ;

Couriel, Daniel ;

Kaminski, Mark ;

Vij, Ravi .

BLOOD, 2012, 120 (09) :1801-1809

[8] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma [J].

Korde, Neha ;

Roschewski, Mark ;

Zingone, Adriana ;

Kwok, Mary ;

Manasanch, Elisabet E. ;

Bhutani, Manisha ;

Tageja, Nishant ;

Kazandjian, Dickran ;

Mailankody, Sham ;

Wu, Peter ;

Morrison, Candis ;

Costello, Rene ;

Zhang, Yong ;

Burton, Debra ;

Mulquin, Marcia ;

Zuchlinski, Diamond ;

Lamping, Liz ;

Carpenter, Ashley ;

Wall, Yvonne ;

Carter, George ;

Cunningham, Schuyler C. ;

Gounden, Verena ;

Sissung, Tristan M. ;

Peer, Cody ;

Maric, Irina ;

Calvo, Katherine R. ;

Braylan, Raul ;

Yuan, Constance ;

Stetler-Stevenson, Maryalice ;

Arthur, Diane C. ;

Kong, Katherine A. ;

Weng, Li ;

Faham, Malek ;

Lindenberg, Liza ;

Kurdziel, Karen ;

Choyke, Peter ;

Steinberg, Seth M. ;

Figg, William ;

Landgren, Ola .

JAMA ONCOLOGY, 2015, 1 (06) :746-754

[9] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma [J].

Shah, Jatin J. ;

Stadtmauer, Edward A. ;

Abonour, Rafat ;

Cohen, Adam D. ;

Bensinger, William I. ;

Gasparetto, Cristina ;

Kaufman, Jonathan L. ;

Lentzsch, Suzanne ;

Vogl, Dan T. ;

Gomes, Christina L. ;

Pascucci, Natalia ;

Smith, David D. ;

Orlowski, Robert Z. ;

Durie, Brian G. M. .

BLOOD, 2015, 126 (20) :2284-2290

[10] Design and Synthesis of an Orally Bioavailable and Selective Peptide Epoxyketone Proteasome Inhibitor (PR-047) [J].

Zhou, Han-Jie ;

Aujay, Monette A. ;

Bennett, Mark K. ;

Dajee, Maya ;

Demo, Susan D. ;

Fang, Ying ;

Ho, Mark N. ;

Jiang, Jing ;

Kirk, Christopher J. ;

Laidig, Guy J. ;

Lewis, Evan R. ;

Lu, Yan ;

Muchamuel, Tony ;

Parlati, Francesco ;

Ring, Eileen ;

Shenk, Kevin D. ;

Shields, Jamie ;

Shwonek, Peter J. ;

Stanton, Timothy ;

Sun, Congcong M. ;

Sylvain, Catherine ;

Woo, Tina M. ;

Yang, Jinfu .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (09) :3028-3038

← 1 →